The phase 2 FENerations1 study is evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS with pediatric pharmacokinetic and safety findings not yet reported.
|Slideshows|April 20, 2017
AAN 2017: Must-See Sessions
Author(s)Samantha J. Peterson
You won’t want to miss these new features and sessions at this year’s American Academy of Neurology Annual Meeting, April 22-28, in Boston, MA.
Advertisement
We highlight some of the top sessions and new features at this year’s American Academy of Neurology Annual Meeting, taking place in Boston, April 22-28. From aging and dementia to Zika virus, AAN 2017 covers the latest developments in neurology.
Advertisement
Related to this article
One-year data from the phase 3 AQUARELLE study found that divozilimab, an anti-CD20 antibody, reduced relapse risk in patients with neuromyelitis optica spectrum disorder.
The chief research and medical affairs officer at the National MS Society discussed AI-enabled imaging, biomarkers of progression, women's health across the lifespan, and the Society's Campaign to End MS.
Decade of OPERA Data Supports Early Ocrelizumab Treatment Initiation in Relapsing Multiple Sclerosis
A newly published 10-year analysis of the OPERA I and II trials reported that starting ocrelizumab 2 years earlier was associated with less disability accrual in relapsing MS, with no new safety signals.
Clene has filed an NDA seeking accelerated approval of CNM-Au8 for ALS, following 2 missed primary trial endpoints and years of evolving FDA guidance.
In a 16-person placebo-controlled trial, every cognitively unimpaired adult given AV-1959R developed anti-amyloid-beta antibodies, while placebo recipients stayed at baseline.
Newly presented post hoc analyses examined diazepam nasal spray for status epilepticus in seizure clusters and intervals between clusters in children, alongside real-world data on rescue medication prescribing.
A retrospective 10-center U.S. study found stiripentol reduced convulsive seizure frequency, status epilepticus episodes, and emergency health care use in patients with Dravet syndrome.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Clene Submits NDA Seeking Accelerated Approval for ALS Drug
2
Decade of OPERA Data Supports Early Ocrelizumab Treatment Initiation in Relapsing Multiple Sclerosis
3
First-in-Human Trial Begins for an Antisense Oligonucleotide in KCNT1-Related Epilepsy
4
RGX-202 Meets Primary End Point in Phase 3 Duchenne Trial
5